Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$43.03 USD
+0.05 (0.12%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $43.02 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IONS 43.03 +0.05(0.12%)
Will IONS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IONS
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy?
Other News for IONS
Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS)
Raymond James Raises Ionis Pharmaceuticals (IONS) Price Target to $64 | IONS Stock News
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
Ionis Pharmaceuticals (IONS) Receives Analyst Upgrade and Price Target Increase | IONS Stock News
IONS Stock Update: HC Wainwright & Co. Raises Price Target to $65.00 | IONS Stock News